UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(D) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported):
(Exact name of registrant as specified in its charter)
| (State
or other jurisdiction of incorporation) |
(Commission File Number) | (I.R.S. Employer Identification No.) |
| (Address of Principal Executive Offices) | (Zip Code) |
(
(Registrant’s telephone number, including area code)
Check the appropriate box below if the Form 8-K is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant
to Section 13(a) of the Exchange Act.
Item 4.02 Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim Review.
In light of recent comment letters issued by the U.S. Securities and Exchange Commission (the “SEC”), the management of Science 37 Holdings, Inc. (Formerly LifeSci Acquisition II Corp.) (the “Company”) has re-evaluated LifeSci Acquisition II Corp.’s prior application of ASC 480-10-S99-3A to its accounting classification of the redeemable shares of Class A common stock, par value $0.0001 per share (the “Public Shares”), issued as part of the units sold in the Company’s initial public offering (the “IPO”) on November 24, 2020.
The following changes resulting from the re-evaluation had no impact on the Company’s cash position and cash held in the trust account established in connection with the IPO (the “Trust Account”) and solely relate to information filed with the SEC prior to October 6, 2021, the date the merger between Science 37, Inc. and LifeSci Acquisition II Corp. was consummated.
On December 16, 2021, the Company’s current management and the Audit Committee of the Company’s board of directors (the “Audit Committee”), after consultation with WithumSmith+Brown, PC (“Withum”), the Company’s prior independent registered public accounting firm, concluded that LifeSci Acquisition II Corp.’s previously issued (i) audited balance sheet as of June 30, 2021, as previously restated in the Company’s Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2021, filed with the SEC on November 15, 2021 (the “Q1 Form 10-Q”), (ii) unaudited interim financial statements included in the Q1 Form 10-Q, (iii) unaudited interim financial statements included in the Company’s Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2021, filed with the SEC on May 17, 2021, and (iv) unaudited interim financial statements included in the Company’s Quarterly Report on Form 10-Q for the quarterly period ended December 31, 2020, filed with the SEC on February 2, 2021 (collectively, the “Affected Periods”), should be restated to report all Public Shares as temporary equity and should no longer be relied upon. As such, the Company has restated its financial statements for the Affected Periods in the Company’s Annual Report on Form 10-K/A for the period ended June 30, 2021, filed with the SEC on December 20, 2021, as described therein.
The Company’s current management has concluded that in light of the classification error in the previously issued financial statements described above, there was a material weakness in the Company’s internal control over financial reporting. The Company’s remediation plan with respect to such material weakness will be described in more detail in the aforementioned Form 10-K/A.
The Company’s management and the Audit Committee have discussed the matters disclosed in this Current Report on Form 8-K pursuant to this Item 4.02 with Withum.
2
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Science 37 Holdings, Inc. | ||
| Date: December 20, 2021 | By: | /s/ David Coman |
| Name: | David Coman | |
| Title: | Chief Executive Officer | |
3
Cover |
Dec. 20, 2021 |
|---|---|
| Cover [Abstract] | |
| Document Type | 8-K |
| Amendment Flag | false |
| Document Period End Date | Dec. 20, 2021 |
| Entity File Number | 001-39727 |
| Entity Registrant Name | Science 37 Holdings, Inc. |
| Entity Central Index Key | 0001819113 |
| Entity Tax Identification Number | 84-4278203 |
| Entity Incorporation, State or Country Code | DE |
| Entity Address, Address Line One | 600 Corporate Pointe |
| Entity Address, Address Line Two | Suite 320 |
| Entity Address, City or Town | Culver City |
| Entity Address, State or Province | CA |
| Entity Address, Postal Zip Code | 90230 |
| City Area Code | 984 |
| Local Phone Number | 377-3737 |
| Written Communications | false |
| Soliciting Material | false |
| Pre-commencement Tender Offer | false |
| Pre-commencement Issuer Tender Offer | false |
| Title of 12(b) Security | Common Stock, par value $0.0001 per share |
| Trading Symbol | SNCE |
| Security Exchange Name | NASDAQ |
| Entity Emerging Growth Company | true |
| Elected Not To Use the Extended Transition Period | false |
'0RIC^$%?NUV_BF 4 6E